Drug intelligence / Profile preview

anti-TrkB agonist antibody

Development stage: Preclinical
Lead developer: Staidson Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Staidson Biopharmaceutical is developing an anti-TrkB agonist monoclonal antibody for the treatment of depression. This therapeutic candidate is designed to mimic the activity of brain-derived neurotrophic factor (BDNF) by binding to and activating the Tropomyosin receptor kinase B (TrkB) receptor. Activation of the BDNF/TrkB signaling pathway is associated with neurotrophic effects and antidepressant activity, potentially offering a novel mechanism for managing mood disorders. The program is currently in the preclinical stage of development.

Other names: anti-TrkB agonist antibody

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on anti-TrkB agonist antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-TrkB agonist antibody.

Explore the full profile